Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus Cyclophosphamide (TC) as adjuvant chemotherapy for node positive breast cancer
Not Applicable
- Conditions
- BreastCancer
- Registration Number
- JPRN-UMIN000001077
- Lead Sponsor
- Kinki Multidisciplinary Breast Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have received any prior therapy (hormonal therapy, chemotherapy, etc.) Pregnant or lactation women History of hypersensitivity reaction to drugs formulated with polysorbate Distant metastasis Patients judged by the investigator to be unfit to be enrolled into the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of planned treatment cycles
- Secondary Outcome Measures
Name Time Method toxicity Mean delivered treatment course Relative dose-intensity